Riskpilot← Back to searchSign inGet full accessSE Endoskopi AB
ABActiveOrg 5563911402Auravägen 13 Lgh 1101Medical specialists activities · NACE 8622Est. 19900 employees
Revenue 2024
—
EBITDA margin
—
-94% vs 2023
Equity ratio
38.9%
Financial strength
Net profit 2024
SEK 1K
+125% vs 2023
| Revenue | — | — |
| EBITDA | SEK -297K | -94% |
| Net profit | SEK 1K | +125% |
| Total assets | SEK 2,9M | +0% |
| Equity | SEK 1,1M | +0% |
| Employees | 0 | — |
Legal name
SE Endoskopi AB
Org number
5563911402
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
8 maj 1990
Share capital
SEK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva medicinsk verksamhet med konsultationer och behandling samt konsultverksamhet inom företagsledning och företagsutveckling. Därutöver kan bolaget äga, förvalta och handla med värdepapper och fastigheter samt idka därmed förenlig verksamhet.
Address
Auravägen 13 Lgh 1101
Phone
+4686052451
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 1 239 | 0 | 0 | 0 | — |
| Staff expenses | — | — | −33 | −33 | −33 |
| EBITDA | −109 | −368 | −267 | −153 | −297 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | −109 | −368 | −267 | −153 | −297 |
| Net financials | −24 | −40 | −1 | −1 | −2 |
| Profit before tax | −133 | 142 | −268 | −5 | 1 |
| Tax | −0 | −7 | — | — | — |
| Net profit | −133 | 135 | −268 | −5 | 1 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2 959 | 2 905 | 2 881 | 2 888 | 2 880 |
| Equity | 1 259 | 1 393 | 1 125 | 1 120 | 1 121 |
| Long-term debt | 52 | 0 | — | — | — |
| Short-term debt | 1 649 | 1 512 | 1 756 | 1 768 | 1 759 |
| Total debt | 1 701 | 1 512 | 1 756 | 1 768 | 1 759 |
EBITDA margin
-29725200.0%
This company
15.8%
Market median
-188134277% vs market
20202024
Equity ratio
38.9%
This company
38.2%
Market median
+2% vs market
20202024
Return on equity
0.1%
This company
18.4%
Market median
-99% vs market
20202024
Net profit margin
119000.0%
This company
8.1%
Market median
+1469036% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
1.57×
This company
0.62×
Market median
-153% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2020 | |
| Deputy Board Member | 2022 | |
| Former (1) | ||
| Deputy Board Member | 2020 – 2020 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
J E Cellanalys AB
SE Endoskopi AB Board members of SE Endoskopi AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Martin Odd Sverker Ericson | Board of Directors | 0 companies |
| Jan Lars-Erik Ericson | Deputy Board Member | 0 companies |
| Siri Linnea Luong Ericson | Deputy Board Member | 0 companies |